Determining the anti-coagulant-independent anti-cancer effects of heparin

British Journal of Cancer

Volumn 103, Issue 4, 2010, Pages 593-594

  Solari, V ^a   Jesudason, E C ^a,b   Turnbull, J E ^a   Yates, E A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CELL AGGREGATION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; FIBRIN DEPOSITION; LETTER; MICROMETASTASIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOSIS; TUMOR MICROENVIRONMENT; WOUND HEALING IMPAIRMENT;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; HEPARIN; HUMANS; NEOPLASMS;

EID: 77955509923     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605808     Document Type: Letter

References (16)

1. Bishop JR, Schuksz Esko JD (2007) Heparan sulphate proteoglycans fine-tune physiology. Nature 446: 1030-1037
2. Boccaccio C, Comoglio PM (2005) A functional role for hemostasis in early cancer development. Cancer Res 65: 8579-8582
3. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98: 3352-3357
4. Cunningham MS, Preston RJ, O'Donnell JS (2009) Does anti-thrombotic therapy improve survival in cancer patients? Blood Rev 3: 129-135
5. Dvorak HF (1986) Tumors: wounds that do not heal. NEJM 315: 1650-1659
6. Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, van Kuppevelt TH, Zcharia E, Vlodavsky I, Lindahl U, Li JP (2007) Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 3: 773-778
7. Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5(7): 526-542
8. Kakkar AK, Macbeth F (2010) Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer 102: S24-S29
9. Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102: S2-S9
10. Norrby K (1993) Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis Suppl 1: 141-149
11. Ori A, Wilkinson MC, Fernig DG (2008) The heparanome and regulation of cell function: structures, functions and challenges. Front Biosci 13: 4309-4338
12. Patey SJ, Edwards EA, Yates EA, Turnbull JE (2006) Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases. J Med Chem 49: 6129-6132
13. Rickles FR, Falanga A (2009) Activation of clotting factors in cancer. Cancer Treat Res 148: 31-41
14. Skidmore MA, Dumax-Vorzet AF, Guimond SE, Rudd TR, Edwards EA, Turnbull JE, Craig AG, Yates EA (2008) Disruption of rosetting in Plasmodium falciparum malaria with chemically modified heparin and low molecular weight derivatives possessing reduced anticoagulant and other serine protease inhibition activities. J Med Chem 51: 1453-1458
15. Yates EA, Santini F, Guerrini M, Naggi A, Torri G, Casu B (1996) 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res 294: 15-27
16. Zielinski CC, Hejna M (2000) Warfarin for cancer prevention. N Engl J Med 342: 1991-1993